Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients.

Next Previous
Trial Profile

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idebenone (Primary)
  • Indications Cardiomyopathies; Friedreich's ataxia
  • Focus Therapeutic Use
  • Acronyms IONIA
  • Sponsors Santhera Pharmaceuticals

Most Recent Events

  • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
  • 01 Mar 2011 Results for secondary cardiac endpoints published in the American Heart Journal.
  • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top